Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184632 | 0.88 | ALDH1A1 (0.51) | ALDH1A1USP2POLBGAALMNA | |
| SCHEMBL16027883 | 0.83 | KDM4E (0.52) | ALDH1A1POLBGAAPKMHPGD | |
| SCHEMBL16027860 | 0.82 | ALDH1A1 (0.48) | ALDH1A1POLBGAAPKMHPGD | |
| SCHEMBL3178043 | 0.80 | USP2 (0.46) | ALDH1A1USP2POLBLMNAMAPT | |
| SCHEMBL836795 | 0.80 | ALDH1A1 (0.49) | ALDH1A1USP2POLBLMNAPKM | |
| SCHEMBL22800897 | 0.78 | ALDH1A1 (0.50) | ALDH1A1USP2POLBGAALMNA | |
| SCHEMBL837415 | 0.77 | TSHR (0.49) | ALDH1A1USP2POLBLMNAPKM | |
| SCHEMBL5719366 | 0.76 | ALDH1A1 (0.64) | ALDH1A1USP2POLBGAALMNA | |
| SCHEMBL835360 | 0.75 | TSHR (0.52) | ALDH1A1POLBHPGDMEN1KMT2A | |
| SCHEMBL3187590 | 0.74 | TSHR (0.46) | ALDH1A1USP2POLBLMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112724141-A | GPR109A protein receptor inhibitor and preparation and application thereof | 南京艾美斐生物医药科技有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | disclosed |
| EP-1781657-B1 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2272848-B1 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8268839-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| EP-1912992-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1912991-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| EP-1781657-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007017261-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017262-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2005077950-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135456-A1 | Medicaments with hm74a receptor activity | HCAR1, GPR84, HCAR3 | ALDH1A1 1397/4885USP2 3953/4885POLB 3864/4885 |
| US-20150080418-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | ALDH1A1 305/4885USP2 4163/4885POLB 2508/4885 |
| US-20130150383-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | ALDH1A1 305/4885USP2 4163/4885POLB 2508/4885 |
| US-20100010021-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | ALDH1A1 305/4885USP2 4163/4885POLB 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.